CryoPort (CYRX) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• CryoPort (CYRX) is expected to release its Q2 2025 earnings report on August 5th, with analysts predicting an earnings loss of ($0.20) per share and revenues of $41.74 million.
• The company recently saw its stock price affected, opening at $7.65 and down 2.5% as it approaches earnings release, with a market cap of $383.57 million.
• Analysts have mixed opinions on CryoPort’s stock, with price targets ranging from $7.00 to $15.00 and an overall rating of "Moderate Buy" based on recent evaluations.

CryoPort (NASDAQ:CYRX - Get Free Report) will likely be releasing its Q2 2025 earnings data after the market closes on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $41.74 million for the quarter. CryoPort has set its FY 2025 guidance at EPS.

CryoPort (NASDAQ:CYRX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01. CryoPort had a negative net margin of 50.15% and a negative return on equity of 11.03%. The company had revenue of $41.04 million during the quarter, compared to the consensus estimate of $56.19 million. On average, analysts expect CryoPort to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CryoPort Price Performance

Shares of NASDAQ CYRX traded down $0.06 during mid-day trading on Friday, reaching $7.27. 485,962 shares of the company were exchanged, compared to its average volume of 408,366. The stock has a market capitalization of $364.52 million, a PE ratio of -3.11 and a beta of 1.88. The company's 50 day moving average price is $7.03 and its 200 day moving average price is $6.59. CryoPort has a 52 week low of $4.58 and a 52 week high of $9.66. The company has a quick ratio of 5.24, a current ratio of 5.56 and a debt-to-equity ratio of 0.51.

Insider Activity at CryoPort

In other news, insider Edward J. Zecchini sold 51,500 shares of CryoPort stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $6.84, for a total value of $352,260.00. Following the transaction, the insider owned 90,411 shares of the company's stock, valued at $618,411.24. The trade was a 36.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ramkumar Mandalam sold 40,728 shares of the business's stock in a transaction that occurred on Tuesday, July 22nd. The stock was sold at an average price of $7.24, for a total transaction of $294,870.72. Following the sale, the director directly owned 92,328 shares in the company, valued at approximately $668,454.72. This represents a 30.61% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 490,447 shares of company stock worth $3,337,198. Corporate insiders own 10.00% of the company's stock.

Institutional Trading of CryoPort

An institutional investor recently raised its position in CryoPort stock. AQR Capital Management LLC lifted its position in CryoPort, Inc. (NASDAQ:CYRX - Free Report) by 285.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 262,596 shares of the company's stock after purchasing an additional 194,482 shares during the quarter. AQR Capital Management LLC owned about 0.52% of CryoPort worth $1,597,000 at the end of the most recent reporting period. Institutional investors own 92.90% of the company's stock.

Analyst Ratings Changes

CYRX has been the topic of a number of analyst reports. BTIG Research decreased their price objective on shares of CryoPort from $13.00 to $10.00 and set a "buy" rating on the stock in a research report on Monday, July 7th. Guggenheim restated a "buy" rating and issued a $10.00 price objective on shares of CryoPort in a research report on Wednesday, April 16th. Needham & Company LLC restated a "buy" rating and issued a $11.00 price objective on shares of CryoPort in a research report on Thursday, May 8th. Stephens began coverage on shares of CryoPort in a research report on Tuesday, July 22nd. They issued an "overweight" rating and a $13.00 price objective on the stock. Finally, Morgan Stanley reduced their price target on shares of CryoPort from $8.00 to $7.00 and set an "equal weight" rating on the stock in a research report on Monday, May 5th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $10.63.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.